JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis | Zendy

Linda M. Scott | Zendy; Wei Tong | Zendy; Ross L. Levine | Zendy; Mike Scott | Zendy; Philip Beer | Zendy; Michael R. Stratton | Zendy; P. Andrew Futreal | Zendy; Wendy N. Erber | Zendy; Mary Frances McMullin | Zendy; Claire Harrison | Zendy; Alan J. Warren | Zendy; D. Gary Gilliland | Zendy; Harvey F. Lodish | Zendy; Anthony R. Green | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis

Author(s) -

Linda M. Scott,

Wei Tong,

Ross L. Levine,

Mike Scott,

Philip Beer,

Michael R. Stratton,

P. Andrew Futreal,

Wendy N. Erber,

Mary Frances McMullin,

Claire Harrison,

Alan J. Warren,

D. Gary Gilliland,

Harvey F. Lodish,

Anthony R. Green

Publication year - 2007

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa065202

Subject(s) - polycythemia vera , janus kinase 2 , myelofibrosis , erythropoietin , exon , erythropoietin receptor , medicine , cancer research , essential thrombocythemia , mutation , erythropoiesis , polycythemia rubra vera , bone marrow , myeloproliferative disorders , microbiology and biotechnology , immunology , biology , anemia , gene , genetics , receptor

The V617F mutation, which causes the substitution of phenylalanine for valine at position 617 of the Janus kinase (JAK) 2 gene (JAK2), is often present in patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. However, the molecular basis of these myeloproliferative disorders in patients without the V617F mutation is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research